Last updated: February 21, 2026
What is the Drug with NDC 00093-5420?
NDC 00093-5420 corresponds to Prolia (denosumab), a monoclonal antibody indicated for osteoporosis treatment, juvenile osteoporosis, and certain cancer-related bone conditions.
Market Size and Segment Overview
Global Osteoporosis Market
- Estimated value in 2022: approximately $5 billion.
- Compound annual growth rate (CAGR): 3.5% (2023–2028).
- Drivers: aging populations, increasing osteoporosis prevalence, improved diagnosis rates.
Key Players
- Amgen (Prolia)
- Radius Health (Already in the market for similar indications with alternative therapies)
- Innovative biotechs exploring biosimilars and biosimilar competitors.
Geographic Penetration
- North America accounts for 45% of sales.
- Europe: 30%
- Asia-Pacific: 15%
- Rest of world: 10%
Market Share
- Prolia holds around 65% of the denosumab market segment.
- Competitive options include generic bisphosphonates and other biologics.
Pricing Landscape
Current Wholesale Acquisition Cost (WAC)
- US: approximately $2,600 per injection (including a standard dose of 60 mg every six months).
- European markets: approximately €1,850–€2,200 per dose, depending on country.
Reimbursement and Pricing Dynamics
- Insurance reimbursement covers 80–90% in the US.
- Cost-sharing programs and biosimilars are influencing net prices.
Biosimilar Considerations
- First biosimilar versions are approved and entering markets in Europe.
- US biosimilar approval expected within 2–3 years, potentially reducing prices by 15–25%.
Price Trends and Projections
Short-term (Next 1–2 Years)
- US list price: remains stable at around $2,600 per dose.
- Market pressures from biosimilar competition expected to stabilize net prices at 10–15% lower than current levels due to negotiated discounts.
Medium-term (Next 3–5 Years)
- Anticipated biosimilar entry in the US: 2024–2025.
- Expected impact: 20–30% reduction in net prices.
- Prices in Europe could decrease by 25–30% as biosimilars gain market share.
Long-term (Beyond 5 Years)
- Market maturity and increased biosimilar competition could lead to a 35–50% decrease in net prices.
- Innovative pricing models, including value-based agreements, could influence actual transaction prices.
Economic and Regulatory Factors
- US Biosimilar Approval Pathways: 351(k) pathway simplifies biosimilar entry.
- Patent expirations: Prolia's patent expired in 2024 in the US, enabling biosimilar competition.
- Reimbursement policy shifts: Potential for tighter control on drug prices, especially for high-cost biologics.
Investment Implications
- The biosimilar pipeline and patent cliffs are primary price reduction drivers.
- Pricing stability expected in the short term, but significant discounts anticipated after biosimilar market entry.
- Companies with biosimilar product portfolios are positioned to benefit from market share gains.
Market Entry and Commercial Strategy
- Companies should emphasize cost competitiveness and biosimilar development.
- Differentiation strategies could focus on indications, administration convenience, and patient support programs.
- Payer negotiations will be critical to maintaining price levels and market share.
Summary Table of Price Trends
| Time Frame |
Expected Price Trend |
Estimated Price Reduction |
Key Factors |
| 1–2 years |
Stable with minor discounts |
0-10% |
Biosimilar approval pending |
| 3–5 years |
Entry of biosimilars impacts market |
20-30% |
Biosimilar market penetration |
| >5 years |
Market saturation and increased competition |
35-50% |
Patent expiration and market maturation |
Key Takeaways
- NDC 00093-5420 (Prolia) dominates the osteoporosis biologic segment with significant market share.
- Current US list prices hover around $2,600 per dose, with stable short-term outlook.
- Biosimilar competition targeting the patent expiration in 2024 will likely drive prices downward over the medium and long term.
- European markets see similar trends, with price reductions forecasted post-biosimilar entry.
- Strategic positioning around biosimilars, cost structures, and payer negotiations remains critical to maintaining profitability.
FAQs
How will biosimilar entry impact Prolia’s pricing?
Biosimilar entry is expected to reduce net prices by 20–30% in the US and Europe within 3–5 years, driven by increased competition and market share shifts.
When does patent expiration occur for Prolia?
Prolia’s key patents expired in 2024 in the US, opening the pathway for biosimilar approvals and competition.
Are there any regulatory hurdles for biosimilars in this segment?
US biosimilars follow the 351(k) pathway, which streamlines approval. Europe employs similar pathways, but market uptake varies due to reimbursement and prescribing practices.
What factors influence the price trajectory of biologics like Prolia?
Patent protection, biosimilar market entry, reimbursement policies, and market demand significantly influence pricing.
How should companies prepare for biosimilar competition?
Prioritize biosimilar development, negotiate with payers for favorable formulary placement, and differentiate via indications or administration methods.
References
[1] Grand View Research. (2022). Osteoporosis Drugs Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2023). Biologics and Biosimilars Data and Market Outlook.
[3] FDA. (2022). Biosimilar Approval Pathways.
[4] European Medicines Agency. (2022). Biosimilar Medicines Market Overview.
[5] Amgen. (2023). Prolia Product Information and Market Data.
